<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003916</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-22972-26991</org_study_id>
    <secondary_id>EORTC-22972</secondary_id>
    <secondary_id>EORTC-26991</secondary_id>
    <secondary_id>MRC-BR10</secondary_id>
    <nct_id>NCT00003916</nct_id>
  </id_info>
  <brief_title>Standard Radiation Therapy With or Without Stereotactic Radiation Therapy in Treating Patients With Glioma</brief_title>
  <official_title>Focal Fractionated Conformal Stereotactic Boost Following Conventional Radiotherapy of High Grade Gliomas: A Randomized Phase III Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells and may be an
      effective treatment for patients with glioma. Stereotactic radiation therapy may be able to
      deliver x-rays directly to the tumor and cause less damage to normal tissue. It is not yet
      known if standard radiation therapy is more effective when followed by stereotactic radiation
      therapy.

      PURPOSE: Randomized phase III trial to compare the effectiveness of standard radiation
      therapy with or without stereotactic radiation therapy in treating patients who have glioma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Compare the effect of adjuvant conventional radiotherapy with or without
      fractionated stereotactic boost radiotherapy on survival in patients with high grade glioma.
      II. Compare the quality of life of these patients after these therapies.

      OUTLINE: This is a randomized study. Patients are stratified according to WHO disease grade
      (III vs IV), center, and age (under 40 vs 40 and over). Patients are randomized to undergo
      stereotactic radiotherapy or no further treatment after conventional radiotherapy. Patients
      undergo conventional radiotherapy once or twice a day for up to 6 weeks. Patients randomized
      to receive additional treatment receive stereotactically guided conformal boost radiotherapy
      for 4 days, within 4 weeks after completion of conventional radiotherapy. Quality of life is
      assessed before radiotherapy, then at follow up visits. Patients are followed every 3 months
      for 1 year, every 6 months for 1 year, and then annually thereafter.

      PROJECTED ACCRUAL: A total of 605 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 1999</start_date>
  <primary_completion_date type="Actual">December 2001</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">25</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>stereotactic radiosurgery</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically proven WHO grade III or IV glioma at primary
        diagnosis that enhance on preoperative imaging Glioblastoma Anaplastic astrocytoma
        Gliosarcoma Tumor volume no greater than 4.0 cm in maximum diameter on preoperative CT or
        MRI No prior histology of WHO grade I or II glioma Astrocytoma Oligodendroglioma No
        brainstem or infratentorial tumor No multifocal glioma Safe to treat tumor stereotactically
        No close proximity to critical structures, e.g., optic chiasm

        PATIENT CHARACTERISTICS: Age: 18 to 65 Performance status: WHO 0 or 1 Life expectancy: Not
        specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Other:
        Able to tolerate full course of conventional radiotherapy No prior or concurrent medical
        condition that would preclude study therapy No prior malignancies within 5 years except
        nonmelanomatous skin cancer or carcinoma in situ of the cervix

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior
        chemotherapy No concurrent adjuvant chemotherapy Endocrine therapy: Concurrent steroids
        allowed Radiotherapy: See Disease Characteristics No prior radiotherapy to the head and
        neck area No prior radiotherapy to the brain No more than 6 weeks since other prior
        radiotherapy Surgery: See Disease Characteristics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brigitta Baumert, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>UniversitaetsSpital Zuerich</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3181</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Klinik I</name>
      <address>
        <city>Dresden</city>
        <zip>D-01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaet Wuerzburg/Hautkrankheiten</name>
      <address>
        <city>Wuerzburg</city>
        <zip>D-97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vrije Universiteit Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <zip>1001HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Catala d'Oncologia - Hospital Duran i Reynals</name>
      <address>
        <city>Barcelona</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsspital</name>
      <address>
        <city>Zurich</city>
        <zip>CH-8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital</name>
      <address>
        <city>Sutton</city>
        <state>England</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Baumert BG, Brada M, Bernier J, Kortmann RD, Dehing-Oberije C, Collette L, Davis JB. EORTC 22972-26991/MRC BR10 trial: fractionated stereotactic boost following conventional radiotherapy of high grade gliomas. Clinical and quality-assurance results of the stereotactic boost arm. Radiother Oncol. 2008 Aug;88(2):163-72. doi: 10.1016/j.radonc.2008.03.025. Epub 2008 Apr 30.</citation>
    <PMID>18455252</PMID>
  </results_reference>
  <results_reference>
    <citation>Brada M, Baumert B. Focal fractionated conformal stereotactic boost following conventional radiotherapy of high-grade gliomas: a randomized phase III study. A joint study of the EORTC (22972) and the MRC (BR10). Front Radiat Ther Oncol. 1999;33:241-3.</citation>
    <PMID>10549493</PMID>
  </results_reference>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>February 13, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 16, 2004</study_first_posted>
  <last_update_submitted>September 20, 2012</last_update_submitted>
  <last_update_submitted_qc>September 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult glioblastoma</keyword>
  <keyword>adult anaplastic astrocytoma</keyword>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

